| Kent Lake Issues Letter to Quanterix Shareholders Regarding Opposition to the Company's Proposed Merger with Akoya Biosciences |
RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”), a holder of 5.9% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), today highlighted its opposition to the Company's proposed merger (the “Merger”) with Akoya Biosciences (“Akoya”) (NASDAQ: AKYA). Kent Lake has also issued an open letter to all Quanterix shareholders outlining how the Merger significantly undervalues the Company and its intention to take all necessary step. |
businesswire.com |
2025-02-18 17:40:00 |
Czytaj oryginał (ang.) |
| Akoya Biosciences Unveils Strategic Product Roadmap, Powered by the New IO60 and Upcoming Neurobiology Panels |
Rapid menu expansion with new high-plex human and mouse neurobiology panels joining the recently launched Human IO60 and Mouse FFPE IO Panels |
globenewswire.com |
2025-02-05 10:00:00 |
Czytaj oryginał (ang.) |
| Akoya Biosciences Selects Argonaut Manufacturing Services as IVD Manufacturing Partner |
CARLSBAD, Calif.--(BUSINESS WIRE)--Argonaut Manufacturing Services (“Argonaut”), a leading contract development and manufacturing organization serving the biopharma and life sciences industries, and Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, announced today that Argonaut will act as the manufacturing partner for Akoya's IVD assays currently in development. This agreement builds on years of collaboration between Argonaut and Akoya, reflecting Argonaut's prove. |
businesswire.com |
2025-01-28 08:00:00 |
Czytaj oryginał (ang.) |
| Quanterix price target lowered by $4 at TD Cowen, here's why |
Quanterix + Akoya Biosciences +0.39 (+14.72%) |
https://thefly.com |
2025-01-13 09:52:42 |
Czytaj oryginał (ang.) |
| AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA |
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akoya Biosciences, Inc. (NasdaqGS: AKYA) to Quanterix Corporation (NasdaqGM: QTRX). Under the terms of the proposed transaction, shareholders of Akoya will receive 0.318 shares of Quanterix for each share of Akoya that they own. KSF is seeking to determine whether this consideration and the process that led to. |
businesswire.com |
2025-01-10 19:35:00 |
Czytaj oryginał (ang.) |
| Shareholder Alert: Ademi LLP Investigates Whether Akoya Biosciences, Inc. Is Obtaining a Fair Price for Its Public Shareholders |
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Akoya (NASDAQ: AKYA) for possible breaches of fiduciary duty and other violations of law in its transaction with Quanterix. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Akoya stockholders will receive only 0.318 shares of Quanterix common stock for each share of Akoya common stock. |
businesswire.com |
2025-01-10 11:47:00 |
Czytaj oryginał (ang.) |
| AKYA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akoya Biosciences, Inc. Is Fair to Shareholders |
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Akoya Biosciences, Inc. (NASDAQ: AKYA) to Quanterix Corporation for 0.318 shares of Quanterix common stock for each share of Akoya common stock is fair to Akoya shareholders. Halper Sadeh encourages Akoya shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersad. |
businesswire.com |
2025-01-10 10:21:00 |
Czytaj oryginał (ang.) |
| Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers |
BILLERICA, Mass. and MARLBOROUGH, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ: AKYA), The Spatial Biology Company®, today announced a definitive merger agreement under which Quanterix will acquire Akoya in an all-stock transaction. The transaction will create the first integrated solution for ultra-sensitive detection of blood- and tissue-based protein biomarkers. |
businesswire.com |
2025-01-10 09:00:00 |
Czytaj oryginał (ang.) |
| Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions |
Akoya expands clinical test menu, exclusively licensing the global rights to develop and commercialize NeraCare's Immunoprint test for prognostication of disease recurrence in early-stage melanoma patients to better guide treatment decisions and potentially increase access to life saving therapies for those patients at high risk of developing metastatic disease Akoya expands clinical test menu, exclusively licensing the global rights to develop and commercialize NeraCare's Immunoprint test for prognostication of disease recurrence in early-stage melanoma patients to better guide treatment decisions and potentially increase access to life saving therapies for those patients at high risk of developing metastatic disease |
globenewswire.com |
2024-12-10 10:15:00 |
Czytaj oryginał (ang.) |
| Akoya Biosciences, Inc. (AKYA) Q3 2024 Earnings Call Transcript |
Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Company Participants Priyam Shah - Head, IR Brian McKelligon - CEO Johnny Ek - CFO Conference Call Participants William Bonello - Craig-Hallum Mason Carrico - Stephens Kyle Mikson - Canaccord David Westenberg - Piper Tejas Savant - Morgan Stanley Subbu Nambi - Guggenheim Securities Mark Massaro - BTIG Operator Hello and thank you for standing by. Welcome to the Akoya Biosciences Third Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2024-11-14 23:43:08 |
Czytaj oryginał (ang.) |
| Akoya Biosciences (AKYA) Reports Q3 Loss, Lags Revenue Estimates |
Akoya Biosciences (AKYA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.26 per share a year ago. |
zacks.com |
2024-11-14 20:10:39 |
Czytaj oryginał (ang.) |
| Akoya Biosciences Reports Third Quarter 2024 Financial Results |
MARLBOROUGH, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the third quarter ending September 30, 2024. |
globenewswire.com |
2024-11-14 18:00:00 |
Czytaj oryginał (ang.) |
| Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024 |
MARLBOROUGH, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the third quarter of 2024 after the market closes on Thursday, November 14, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. |
globenewswire.com |
2024-10-28 10:30:00 |
Czytaj oryginał (ang.) |
| Akoya's Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy |
Consortium includes top universities, hospitals and industry partners, led by the Francis Crick Institute and The Royal Marsden NHS Foundation Trust |
globenewswire.com |
2024-10-07 12:00:00 |
Czytaj oryginał (ang.) |
| Akoya Biosciences Announces Scott Mendel as Chairman of the Board of Directors |
MARLBOROUGH, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), the Spatial Biology Company®, today announced Scott Mendel has been appointed as Chairman of its Board, effective October 2, 2024. Mr. Mendel succeeds Robert Shepler, founding Chairman, who will remain on Akoya's board. Mr. Mendel has served as a member of Akoya's board of directors since June 2021 and has over 30 years of financial and operational management experience. |
globenewswire.com |
2024-10-03 20:00:00 |
Czytaj oryginał (ang.) |
| Akoya Biosciences, Inc. (AKYA) Q2 2024 Earnings Call Transcript |
Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q2 2024 Earnings Conference Call August 5, 2024 5:00 PM ET Corporate Participants Priyam Shah - Head, Investor Relations Brian McKelligon - Chief Executive Officer Johnny Ek - Chief Financial Officer Conference Call Participants William Bonello - Craig-Hallum Kyle Mikson - Canaccord Tejas Savant - Morgan Stanley David Westenberg - Piper Sandler Rachel Vatnsdal - JPMorgan Ricki Levitus - Guggenheim Vivian Bais - BTIG Tim Cheung - Capital One Mason Carrico - Stephens Operator Good day and thank you for standing by. Welcome to the Akoya Biosciences Second Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2024-08-06 02:19:08 |
Czytaj oryginał (ang.) |
| Akoya Biosciences (AKYA) Reports Q2 Loss, Misses Revenue Estimates |
Akoya Biosciences (AKYA) came out with a quarterly loss of $0.27 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.51 per share a year ago. |
zacks.com |
2024-08-05 22:10:23 |
Czytaj oryginał (ang.) |
| Akoya Biosciences Reports Second Quarter 2024 Financial Results |
MARLBOROUGH, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the second quarter ending June 30, 2024. |
globenewswire.com |
2024-08-05 20:00:00 |
Czytaj oryginał (ang.) |
| Akoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor Conferences |
MARLBOROUGH, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the second quarter of 2024 after the market closes on Monday, August 5, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. |
globenewswire.com |
2024-07-15 20:00:00 |
Czytaj oryginał (ang.) |
| Lab Instrument Industry Update - New Commercial Entrants |
Lab Instrument and Services providers in the healthcare industry can generate high recurring revenues. Many loss-making instrument makers in the industry may not provide meaningful returns and carry high risks. Cytek stands out as the best opportunity in the sector due to strong growth and manageable losses. |
seekingalpha.com |
2024-05-23 13:17:40 |
Czytaj oryginał (ang.) |
| Akoya Biosciences, Inc. (AKYA) Q1 2024 Earnings Call Transcript |
Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q1 2024 Earnings Conference Call May 13, 2024 5:00 PM ET Company Participants Priyam Shah - Head, IR Brian McKelligon - CEO Johnny Ek - CFO Conference Call Participants Kyle Mikson - Canaccord David Westenberg - Piper Sandler Mark Massaro - BTIG Tejas Savant - Morgan Stanley Subhalaxmi Nambi - Guggenheim Rachel Vatnsdal - JP Morgan Mason Carrico - Stephens Timothy Chiang - Capital One Operator Good day and thank you for standing by. Welcome to the Akoya Biosciences First Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2024-05-18 00:36:03 |
Czytaj oryginał (ang.) |
| Akoya Biosciences (AKYA) Reports Q1 Loss, Lags Revenue Estimates |
Akoya Biosciences (AKYA) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.49 per share a year ago. |
zacks.com |
2024-05-13 22:36:07 |
Czytaj oryginał (ang.) |
| Akoya Biosciences Reports First Quarter 2024 Financial Results |
MARLBOROUGH, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2024. |
globenewswire.com |
2024-05-13 20:00:00 |
Czytaj oryginał (ang.) |
| Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients |
Leveraging Akoya's market-leading PhenoImager HT platform and clinical development expertise with NeraCare's Immunoprint test and best-in-class clinical data, the partnership will focus on increasing access to life saving therapies for early-stage melanoma patients. Leveraging Akoya's market-leading PhenoImager HT platform and clinical development expertise with NeraCare's Immunoprint test and best-in-class clinical data, the partnership will focus on increasing access to life saving therapies for early-stage melanoma patients. |
globenewswire.com |
2024-05-09 12:00:00 |
Czytaj oryginał (ang.) |
| Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release |
Akoya (AKYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-05-06 15:01:10 |
Czytaj oryginał (ang.) |
| Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts |
MARLBOROUGH, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, has opened its Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts to meet the accelerating demand for its spatial biology solutions and the increased utilization of the company's PhenoCycler®-Fusion and the PhenoImager® HT platforms. |
globenewswire.com |
2024-05-06 12:00:00 |
Czytaj oryginał (ang.) |
| Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows |
MARLBOROUGH, Mass. and SHANGHAI, China, May 02, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, and Shanghai KR Pharmtech, a leading company providing molecular diagnostic solutions in China, have jointly announced that KR-HT5, which Akoya Biosciences co-developed with Shanghai KR Pharmtech utilizing the PhenoImager HT technology as its foundation, has received premarket approval from China's National Medical Products Administration (NMPA) to support next generation pathology clinical workflows. |
globenewswire.com |
2024-05-02 12:00:00 |
Czytaj oryginał (ang.) |
| Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024 |
MARLBOROUGH, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2024 after the market close on May 13th, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. |
globenewswire.com |
2024-04-22 20:05:00 |
Czytaj oryginał (ang.) |